RhumbLine Advisers’s Repros Therapeutics Inc. RPRX Stock Holding History

RhumbLine Advisers’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-23,490	Closed	-$202K	–	3226
2015 Q1	$202K	Buy	23,490 +3,900	+20%	+$34.9K	﹤0.01%	2828
2014 Q4	$195K	Buy	19,590 +550	+3%	+$4.69K	﹤0.01%	2829
2014 Q3	$188K	Sell	19,040 -480	-2%	-$7.11K	﹤0.01%	2788
2014 Q2	$338K	Buy	19,520 +779	+4%	+$12.7K	﹤0.01%	2521
2014 Q1	$332K	Sell	18,741 -900	-5%	-$17.4K	﹤0.01%	2473
2013 Q4	$359K	Buy	19,641 +1,400	+8%	+$26.4K	﹤0.01%	2468
2013 Q3	$489K	Buy	18,241 +679	+4%	+$14.6K	﹤0.01%	2223
2013 Q2	$324K	Buy	+17,562	New	+$310K	﹤0.01%	2586

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DCM

Destrier Capital Management New York $144M AUM 7.28% 1-Year Est. Return

RhumbLine Advisers's RPRX Position: Q2 2015 in Review

RhumbLine Advisers sold out of Repros Therapeutics Inc. (RPRX) in Q2 2015, closing a stake of 23,490 shares — an estimated $202K sold.

RhumbLine Advisers first reported a position in RPRX in Q2 2013 and held it in 8 quarters. The position peaked at $489K in Q3 2013. 64 funds tracked by Wall St. Rank hold RPRX as of Q2 2015.

RhumbLine Advisers reported no remaining Repros Therapeutics Inc. position as of Q2 2015 after selling out during the quarter.
RhumbLine Advisers sold 23,490 Repros Therapeutics Inc. shares in Q2 2015, an estimated $202K.
RhumbLine Advisers first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 8 quarters.
RhumbLine Advisers's Repros Therapeutics Inc. position peaked at $489K in Q3 2013.
64 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q2 2015.

Based on RhumbLine Advisers's 13F filing for Q2 2015, filed 4 Aug 2015.